Particle.news
Clinical Trials Drug Development Cell Therapy Clinical Research mRNA Technology Base Editing Adeno-Associated Virus Research Funding CRISPR Technology Viral Vectors RNA Engineering Gene Editing Technologies AAV Capsids Messenger RNA Gene-Silencing Technology ELEVIDYS Collaboration RNA Therapy Immunotherapy FDA Approval Transferrin Neurodevelopmental Disorders Stem Cell Research Protein Research HIV Research Therapeutic Approaches Company Performance In Vivo Products COVID-19 Vaccines RNA Therapeutics Regulation Personalized Medicine Neurological Applications Clinical Development Regulatory Framework Clinical Applications Cellular Response Extracellular Vesicles Experimental Treatments mRNA Applications Organ Replacement Genetic Disorders Preclinical Models uniQure RNA Mechanisms Cell Engineering Cancer Treatments Xenotransplantation Duchenne Muscular Dystrophy Exon Skipping Regulatory Affairs RNA Medicines Medical Treatments Immunosuppression Prime Medicine Gene Regulation Therapeutic Applications Vaccines RNA Editing
Reporting that the patient’s death and her family’s roughly $860,000 funding were omitted from a February Nature paper has raised urgent questions about consent and oversight.
